Factors affecting pharmacokinetic variability following doxorubicin and docetaxel-based therapy.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  European Journal of Cancer

• Publication date

  2004-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/J.EJCA.2003.12.026PMID 15110880
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Pharmacokinetics of doxorubicin in man: dose and schedule dependence

  2004cited by this paper
• Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer

  2004cited by this paper
• Pharmacokinetic study of IV infusions of adriamycin

  2004cited by this paper
• Horseshoes, hand grenades, and body-surface area-based dosing: aiming for a target.

  2003cited by this paper
• The effect of age on the early disposition of doxorubicin

  2003cited by this paper
• Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001.

  2002cited by this paper
• Dosing strategies for anticancer drugs: the good, the bad and body-surface area.

  2002cited by this paper
• Disposition of docetaxel in the presence of P-glycoprotein inhibition by intravenous administration of R101933.

  2002cited by this paper
• How to calculate the dose of chemotherapy

  2002cited by this paper
• Body surface area in dosing anticancer agents: scratch the surface!

  2002cited by this paper
• Pharmacokinetic-Pharmacodynamic Relationships of the Anthracycline Anticancer Drugs

  2002cited by this paper
• Phase I pharmacokinetic and sequence finding study of the combination of docetaxel and methotrexate in patients with solid tumours.

  2002cited by this paper
• Body Surface Area as a Determinant of Pharmacokinetics and Drug Dosing

  2001cited by this paper
• Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Relationships for Docetaxel

  2001cited by this paper
• The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.

  2000cited by this paper
• Pharmacokinetically Guided Administration of Chemotherapeutic Agents

  2000cited by this paper
• A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours

  2000cited by this paper
• A Prospective Pharmacologic Evaluation of Age-Related Toxicity of Adjuvant Chemotherapy in Women with Breast Cancer

  2000cited by this paper
• The impact of obesity and disease on busulfan oral clearance in adults.

  1999cited by this paper
• Clinical pharmacokinetics of doxorubicin in combination with GF120918, a potent inhibitor of MDR1 P-glycoprotein.

  1999cited by this paper
• Determination of doxorubicin and doxorubicinol in plasma of cancer patients by high-performance liquid chromatography.

  1999cited by this paper
• Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?

  1998cited by this paper
• Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia.

  1998cited by this paper
• Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

  1998cited by this paper
• A clinician's guide to chemotherapy pharmacokinetics and pharmacodynamics

  1998cited by this paper
• Age and cytochrome P450‐linked drug metabolism in humans: An analysis of 226 subjects with equal histopathologic conditions

  1997cited by this paper
• Human pharmacokinetic characterization and in vitro study of the interaction between doxorubicin and paclitaxel in patients with breast cancer.

  1997cited by this paper
• Sensitive determination of docetaxel in human plasma by liquid-liquid extraction and reversed-phase high-performance liquid chromatography.

  1997cited by this paper
• Phase I and pharmacologic study of docetaxel and cisplatin in patients with advanced solid tumors.

  1997cited by this paper
• A population pharmacokinetic model for docetaxel (Taxotere): model building and validation.

  1996cited by this paper
• A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation

  1996cited by this paper
• Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative.

  1996cited by this paper
• Should anticancer drug doses be adjusted in the obese patient?

  1995cited by this paper
• Lean body mass, body surface area and epirubicin kinetics.

  1994cited by this paper
• Lean Body Mass as a Predictor of Drug Dosage

  1994cited by this paper
• Is dose normalization to weight or body surface area useful in adults?

  1990cited by this paper
• Carboplatin dosage: prospective evaluation of a simple formula based on renal function.

  1989cited by this paper
• A formula to estimate the approximate surface area if height and weight be known

  1989cited by this paper
• Doxorubicin clearance in the obese.

  1988cited by this paper
• Pharmacokinetic study of i.v. infusions of adriamycin.

  1985cited by this paper
• Interactions between cyclophosphamide and adriamycin metabolism in rats.

  1984cited by this paper
• A program package for simulation and parameter estimation in pharmacokinetic systems.

  1979cited by this paper
• CLINICAL CALORIMETRY: TENTH PAPER A FORMULA TO ESTIMATE THE APPROXIMATE SURFACE AREA IF HEIGHT AND WEIGHT BE KNOWN

  1916cited by this paper

• Lung cancer in women: current evidence and future research priorities.

  2026cites this paper
• Opportunities for Precision Dosing of Cytotoxic Drugs in Non-Small Cell Lung Cancer: Bridging the Gap in Precision Medicine

  2025cites this paper
• Impact of obesity on doxorubicin pharmacokinetics in women with breast cancer.

  2025cites this paper
• The Efficacy Research of Prophylactic PEG-rhG-CSF in Preventing Neutropenia in Early-Stage Breast Cancer Patients Treated With Docetaxel-Based Chemotherapy: A Retrospective Analysis.

  2024cites this paper
• Sex differences in the pharmacokinetics of anticancer drugs: a systematic review

  2024cites this paper
• Real-time monitoring of daunorubicin pharmacokinetics with nanoporous electrochemical aptamer-based sensors in vivo

  2024cites this paper
• Docetaxel population pharmacokinetic modelling and simulation in Chinese cancer patients

  2022cites this paper
• Optimal exposure to docetaxel in adjuvant chemotherapy for early‐stage breast cancer

  2022cites this paper
• Expression and Functional Contribution of Different Organic Cation Transporters to the Cellular Uptake of Doxorubicin into Human Breast Cancer and Cardiac Tissue

  2021cites this paper
• Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control study

  2020cites this paper
• Clinical pharmacokinetics and drug exposure-toxicity correlation study of docetaxel based chemotherapy in Chinese head and neck cancer patients

  2020cites this paper
• An Improved LC-MS/MS Method for Determination of Docetaxel and Its Application to Population Pharmacokinetic Study in Chinese Cancer Patients.

  2020cites this paper
• Is there scope for better individualisation of anthracycline cancer chemotherapy?

  2020influential citation
• Cancer Chemotherapy: The Case for Therapeutic Drug Monitoring.

  2020cites this paper
• Cyclophosphamide dose adjustment based on body weight and albuminemia in elderly patients treated with R-mini-CHOP

  2019cites this paper
• Prediction of docetaxel toxicity in older cancer patients: a Bayesian network approach

  2019cites this paper
• Effect of aprepitant administration on CINV caused by cisplatin multi-day chemotherapy and pharmacokinetics of docetaxel

  2019cites this paper
• Precision Medicine with Imprecise Therapy: Computational Modeling for Chemotherapy in Breast Cancer

  2018cites this paper
• Comparison of the docetaxel concentration in human plasma measured with liquid chromatography-tandem mass spectrometry (LC-MS/MS) and a nanoparticle immunoassay and clinical applications of that assay.

  2017cites this paper
• Pharmacological and Interventional Approaches for Optimizing Taxane Treatment

  2016cites this paper
• Significant effect of age on docetaxel pharmacokinetics in Japanese female breast cancer patients by using the population modeling approach

  2016cites this paper
• Impact of body composition parameters on clinical outcomes in patients with metastatic castrate-resistant prostate cancer treated with docetaxel.

  2016cites this paper
• Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose

  2015cites this paper
• Nonalcoholic steatohepatitis in precision medicine: Unraveling the factors that contribute to individual variability.

  2015cites this paper
• Inter-patient variability in docetaxel pharmacokinetics: A review.

  2015influential citation
• Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review

  2015cites this paper
• Pharmacokinetics of doxorubicin in pregnant women

  2014cites this paper
• Pharmacogenetic effects of regulatory nuclear receptors (PXR, CAR, RXRα and HNF4α) on docetaxel disposition in Chinese nasopharyngeal cancer patients

  2014cites this paper
• Meta-analysis of inter-patient pharmacokinetic variability of liposomal and non-liposomal anticancer agents.

  2014cites this paper
• Genetic variability in the multidrug resistance associated protein-1 (ABCC1/MRP1) predicts hematological toxicity in breast cancer patients receiving (neo-)adjuvant chemotherapy with 5-fluorouracil, epirubicin and cyclophosphamide (FEC).

  2013cites this paper
• Chemotherapy dosing in overweight and obese patients with cancer

  2013cites this paper
• The development and clinical validation of a turbulent-flow liquid chromatography-tandem mass spectrometric method for the rapid quantitation of docetaxel in serum.

  2013cites this paper
• The influence of morbid obesity on the pharmacokinetics and pharmacodynamics of drugs in adolescents and adults : focus on propofol and nadroparin

  2013cites this paper
• An Automated Nanoparticle-Based Homogeneous Immunoassay for Determining Docetaxel Concentrations in Plasma

  2013cites this paper
• Dosing Considerations for Obese Patients Receiving Cancer Chemotherapeutic Agents

  2013influential citation
• The influence of morbid obesity on the pharmacokinetics and pharmacodynamics of drugs in adolescents and adults : focus on propofol and nadroparin.

  2013cites this paper
• Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents

  2012cites this paper
• Appropriate Chemotherapy Dosing for Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline.

  2012cites this paper
• Body-surface area-based chemotherapy dosing: appropriate in the 21st century?

  2012cites this paper
• Appropriate chemotherapy dosing for obese adult patients with cancer: American Society of Clinical Oncology clinical practice guideline.

  2012cites this paper
• Impact of Obesity on Drug Metabolism and Elimination in Adults and Children

  2012cites this paper
• Therapeutic Drug Monitoring for the Individualization of Docetaxel Dosing: A Randomized Pharmacokinetic Study

  2011cites this paper
• Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer

  2010cites this paper
• Impact of the Physiological Effects of Aging on the Pharmacokinetics and Pharmacodynamics of Systemic Breast Cancer Treatment

  2010cites this paper
• Therapeutic drug monitoring in cancer chemotherapy.

  2010cites this paper
• Population pharmacokinetics of doxorubicin in Indian cancer patients using NONMEM

  2009cites this paper
• Optimising care of elderly breast cancer patients: a challenging priority.

  2009cites this paper
• opoisomerase II inhibitors

  2008cites this paper
• Lessons learned from development of docetaxel.

  2008cites this paper
• The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer

  2008cites this paper
• Lessons learned from development of docetaxel

  2008influential citation
• Medicinal cannabis does not influence the clinical pharmacokinetics of irinotecan and docetaxel.

  2007cites this paper
• Long-term health status among survivors of childhood cancer: does sex matter?

  2007cites this paper
• [Use of body weight and body surface area in dosing of anticancer agents in adult patients].

  2007cites this paper
• Pharmacokinetic and pharmacogenetic profiling in solid cancer patients

  2007cites this paper
• Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.

  2007cites this paper
• A Physiologically Based Pharmacokinetic Model of Docetaxel Disposition: from Mouse to Man

  2007cites this paper
• Cytotoxic therapy for the elderly with metastatic breast cancer: a review on safety, pharmacokinetics and efficacy.

  2007cites this paper
• Population Pharmacokinetics and Pharmacodynamics of Doxorubicin and Cyclophosphamide in Breast Cancer Patients

  2007cites this paper
• Lack of Association of Single-Nucleotide Polymorphisms in Pregnane X Receptor, Hepatic Nuclear Factor 4α, and Constitutive Androstane Receptor with Docetaxel Pharmacokinetics

  2007cites this paper
• Flat-fixed dosing versus body surface area based dosing of anticancer drugs in adults: does it make a difference?

  2007cites this paper
• Taxane Therapy for Early Stage Breast Cancer

  2006cites this paper
• A Roadmap to Individualized Irinotecan Dosing

  2006cites this paper
• Clinical Pharmacokinetics of Docetaxel

  2006cites this paper
• Pharmacokinetic Optimization of Docetaxel Dosing

  2006cites this paper
• Evaluation of an alternate dosing strategy for cisplatin in patients with extreme body surface area values.

  2006cites this paper
• Clinical Pharmacology of Cyclophosphamide and Ifosfamide

  2006cites this paper
• Metabolism and Transport of Oxazaphosphorines and the Clinical Implications

  2005cites this paper
• Potential for improvement of docetaxel-based chemotherapy: a pharmacological review

  2005influential citation
• The role of taxanes in the treatment of breast cancer

  2005cites this paper
• Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma

  2005cites this paper
• Factors Affecting Cytochrome P-450 3A Activity in Cancer Patients

  2004cites this paper